Jaya Virmani
Internal Medicine · Menlo Park, CANPI 1629183785
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $890 and has fallen 91.5% since, to $76 in 2025.
Across 99 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$451
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$263
- Therapeuticsmd, Inc.$146
- Pfizer$136
- Neurocrine Biosciences, Inc.$127
- Mylan Specialty L.p.$114
- plus $682 from 15 others
What the payments were for
- Food & beverage$1,918100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $451 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $263 |
| Therapeuticsmd, Inc. | 7 | $146 |
| Pfizer | 8 | $136 |
| Neurocrine Biosciences, Inc. | 5 | $127 |
| Mylan Specialty L.p. | 6 | $114 |
| Bausch Health US, LLC | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $101 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $68 |
| Ardelyx, Inc. | 2 | $57 |
| Merck | 3 | $56 |
| AstraZeneca | 2 | $45 |
| Alfasigma USA, Inc. | 2 | $44 |
| Amgen(2 entities) | 2 | $40 |
| Sanofi Pasteur Inc. | 2 | $40 |
| Novo Nordisk | 1 | $28 |
| IBSA Pharma Inc. | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $19 |
| Shionogi Inc | 1 | $15 |
How this compares
$1,918 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 17 | $30,766 |
| OzempicSemaglutide | 17 | $24,273 |
| EliquisApixaban | 29 | $21,665 |
| MotegrityPrucalopride Succinate | 20 | $17,042 |
| VraylarCariprazine Hcl | 12 | $16,931 |
| BelsomraSuvorexant | 24 | $10,654 |
| Dexlansoprazole DrDexlansoprazole | 25 | $9,284 |
| Dofetilide | 11 | $8,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,591 |
| TrulancePlecanatide | 11 | $5,794 |
| SynthroidLevothyroxine Sodium | 61 | $5,728 |
| Qvar RedihalerBeclomethasone Dipropionate | 19 | $5,151 |
| Nebivolol Hcl | 65 | $3,402 |
| PaxlovidNirmatrelvir/Ritonavir | 21 | $2,797 |
| ValacyclovirValacyclovir Hcl | 40 | $1,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis, Paxlovid | $136 | $55,22867 claims |
| Novo NordiskOzempic | $28 | $24,27317 claims |
| AbbVieVraylar, Synthroid | $451 | $22,65873 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $101 | $17,04220 claims |
| MerckBelsomra | $56 | $10,65424 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $263 | $5,79411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Menlo Park
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.